CA2109697C - Oral-administration forms of a medicament containing pantoprazole - Google Patents

Oral-administration forms of a medicament containing pantoprazole Download PDF

Info

Publication number
CA2109697C
CA2109697C CA002109697A CA2109697A CA2109697C CA 2109697 C CA2109697 C CA 2109697C CA 002109697 A CA002109697 A CA 002109697A CA 2109697 A CA2109697 A CA 2109697A CA 2109697 C CA2109697 C CA 2109697C
Authority
CA
Canada
Prior art keywords
pharmaceutical composition
composition defined
medicament according
core
pellet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002109697A
Other languages
English (en)
French (fr)
Other versions
CA2109697A1 (en
Inventor
Rango Dietrich
Hartmut Ney
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda GmbH
Original Assignee
Altana Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4218617&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2109697(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Altana Pharma AG filed Critical Altana Pharma AG
Priority to CA002524168A priority Critical patent/CA2524168A1/en
Publication of CA2109697A1 publication Critical patent/CA2109697A1/en
Application granted granted Critical
Publication of CA2109697C publication Critical patent/CA2109697C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
CA002109697A 1991-06-17 1992-06-13 Oral-administration forms of a medicament containing pantoprazole Expired - Lifetime CA2109697C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002524168A CA2524168A1 (en) 1991-06-17 1992-06-13 Oral-administration forms of a medicament containing pantoprazole

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CH1788/91-0 1991-06-17
CH178891 1991-06-17
PCT/EP1992/001341 WO1992022284A1 (de) 1991-06-17 1992-06-13 Pantoprazol enthaltende orale darreichungsformen

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA002524168A Division CA2524168A1 (en) 1991-06-17 1992-06-13 Oral-administration forms of a medicament containing pantoprazole

Publications (2)

Publication Number Publication Date
CA2109697A1 CA2109697A1 (en) 1992-12-23
CA2109697C true CA2109697C (en) 2005-11-22

Family

ID=4218617

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002109697A Expired - Lifetime CA2109697C (en) 1991-06-17 1992-06-13 Oral-administration forms of a medicament containing pantoprazole
CA002524168A Expired - Lifetime CA2524168A1 (en) 1991-06-17 1992-06-13 Oral-administration forms of a medicament containing pantoprazole

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA002524168A Expired - Lifetime CA2524168A1 (en) 1991-06-17 1992-06-13 Oral-administration forms of a medicament containing pantoprazole

Country Status (34)

Country Link
US (1) US5997903A (enExample)
EP (2) EP0589981B1 (enExample)
JP (1) JP3338052B2 (enExample)
KR (1) KR100254021B1 (enExample)
CN (1) CN1037932C (enExample)
AT (1) ATE144416T1 (enExample)
AU (1) AU683411B2 (enExample)
BG (1) BG61796B1 (enExample)
CA (2) CA2109697C (enExample)
CZ (1) CZ281697B6 (enExample)
DE (2) DE4219390A1 (enExample)
DK (1) DK0589981T3 (enExample)
ES (1) ES2096080T3 (enExample)
FI (1) FI101598B (enExample)
GR (1) GR3022154T3 (enExample)
HK (1) HK1005851A1 (enExample)
HR (1) HRP920162B1 (enExample)
IE (1) IE77640B1 (enExample)
IL (1) IL102096A (enExample)
LV (1) LV11982B (enExample)
MX (1) MX9202961A (enExample)
NO (1) NO303714B1 (enExample)
NZ (1) NZ243147A (enExample)
PL (1) PL169951B1 (enExample)
RO (1) RO117502B1 (enExample)
RU (1) RU2089180C1 (enExample)
SI (1) SI9200111A (enExample)
SK (1) SK278566B6 (enExample)
TW (1) TW224429B (enExample)
UA (1) UA32525C2 (enExample)
WO (1) WO1992022284A1 (enExample)
YU (1) YU48263B (enExample)
ZA (1) ZA924386B (enExample)
ZW (1) ZW9392A1 (enExample)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4504000A (en) * 1993-04-27 2000-09-07 Sepracor, Inc. Methods and compositions for treating gastric disorders using optically pure (-) pantoprazole
SE9301489D0 (sv) * 1993-04-30 1993-04-30 Ab Astra Veterinary composition
US6875872B1 (en) 1993-05-28 2005-04-05 Astrazeneca Compounds
DE4324014C2 (de) * 1993-07-17 1995-06-08 Byk Gulden Lomberg Chem Fab Verfahren zur Herstellung einer in Wasser rekonstituierbaren Zubereitung
TW280770B (enExample) 1993-10-15 1996-07-11 Takeda Pharm Industry Co Ltd
MX9600857A (es) * 1994-07-08 1997-06-28 Astra Ab Forma de dosificacion i en tabletas, con unidades multiples.
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
ES2094694B1 (es) * 1995-02-01 1997-12-16 Esteve Quimica Sa Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion.
SE9500478D0 (sv) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
US5945124A (en) * 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
DE69631981T2 (de) * 1995-09-21 2005-04-14 Pharma Pass Ii Llc, Irvine Lansoprazolhaltige Arzneizusammensetzung und Herstellungsverfahren
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
SE9702000D0 (sv) * 1997-05-28 1997-05-28 Astra Ab New pharmaceutical formulation
SI9700186B (sl) 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin
ES2137862B1 (es) * 1997-07-31 2000-09-16 Intexim S A Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion.
IN186245B (enExample) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
US6328993B1 (en) * 1997-12-08 2001-12-11 Byk Gulden Lomberg Chemische Fabrik Gmbh Oral administration form for an acid liable active proton pump inhibitor
DK173431B1 (da) 1998-03-20 2000-10-23 Gea Farmaceutisk Fabrik As Farmaceutisk formulering omfattende en 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazol med anti-ulcusaktivitet samt fremgangs
US20020039597A1 (en) 1998-04-20 2002-04-04 Koji Ukai Stabilized compositions containing benzimidazole-type compounds
JP4127740B2 (ja) * 1998-04-20 2008-07-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 安定化したベンズイミダゾール系化合物含有組成物
ES2559766T3 (es) 1998-05-18 2016-02-15 Takeda Pharmaceutical Company Limited Comprimidos disgregables en la boca
ZA9810765B (en) * 1998-05-28 1999-08-06 Ranbaxy Lab Ltd Stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole.
CA2340054C (en) * 1998-08-12 2005-10-18 Byk Gulden Lomberg Chemische Fabrik Gmbh Oral administration form for pyridin-2-ylmethylsulfinyl-1h-benzimidazoles
DE19843413C1 (de) 1998-08-18 2000-03-30 Byk Gulden Lomberg Chem Fab Neue Salzform von Pantoprazol
SI1187601T1 (sl) 1999-06-07 2005-12-31 Altana Pharma Ag Novi pripravek in dajalna oblika, ki obsega kislinsko labilen inhibitor protonske crpalke
SE9902386D0 (sv) * 1999-06-22 1999-06-22 Astra Ab New formulation
ES2168043B1 (es) * 1999-09-13 2003-04-01 Esteve Labor Dr Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido.
TWI268779B (en) * 1999-10-20 2006-12-21 Eisai Co Ltd Method for stabilizing benzimidazole-based compounds
DE19959419A1 (de) 1999-12-09 2001-06-21 Ratiopharm Gmbh Stabile galenische Zubereitungen umfassend ein Benzimidazol und Verfahren zu ihrer Herstellung
EP1108425B1 (en) * 1999-12-16 2005-06-08 Laboratorio Medinfar-Produtos Farmaceuticos, S.A. New stable multi-unitary pharmaceutical preparations containing substituted benzimidazoles
SK287105B6 (sk) * 1999-12-20 2009-12-07 Schering Corporation Dvojvrstvový orálny dávkový prostriedok s predĺženým uvoľňovaním
WO2001045668A2 (en) * 1999-12-20 2001-06-28 Schering Corporation Stable extended release oral dosage composition comprising pseudoephedrine and desloratadine
US6544556B1 (en) 2000-09-11 2003-04-08 Andrx Corporation Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
BR0115989A (pt) * 2000-12-07 2004-01-13 Altana Pharma Ag Preparação farmacêutica na forma de uma suspensão compreendendo um ingrediente ativo instável a ácido
EP1429745A2 (en) 2001-09-28 2004-06-23 McNEIL-PPC, INC. Composite dosage forms having an inlaid portion
US20050163846A1 (en) * 2001-11-21 2005-07-28 Eisai Co., Ltd. Preparation composition containing acid-unstable physiologically active compound, and process for producing same
US20050220870A1 (en) * 2003-02-20 2005-10-06 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
WO2004080439A1 (ja) * 2003-03-12 2004-09-23 Takeda Pharmaceutical Company Limited 高濃度に活性成分を球形核に付着させた医薬組成物
PE20050150A1 (es) * 2003-05-08 2005-03-22 Altana Pharma Ag Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
CL2004000983A1 (es) 2003-05-08 2005-03-04 Altana Pharma Ag Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
AU2003245033A1 (en) * 2003-05-08 2004-11-26 Podili Khadgapathi An improved and stable pharmaceutical composition containing substituted benzimidazoles and a process for its preparation
RU2375048C2 (ru) * 2003-07-17 2009-12-10 Д-Р Редди'С Лабораторис Инк. Фармацевтическая композиция с набухающим покрытием
US20050147663A1 (en) * 2003-07-17 2005-07-07 Mohan Mailatur S. Method of treatment for improved bioavailability
MXPA06000577A (es) * 2003-07-17 2006-07-03 Reddy S Lab Ltd Composiciones farmaceuticas que tienen un recubrimiento hinchable.
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
CA2538910A1 (en) * 2003-09-18 2005-03-24 Altana Pharma Ag Use of known active ingredients as radical scavengers
TWI372066B (en) 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
WO2005034924A1 (en) * 2003-10-14 2005-04-21 Natco Pharma Limited Enteric coated pellets comprising esomeprazole, hard gelatin capsule containing them, and method of preparation
US20050175689A1 (en) * 2003-10-27 2005-08-11 Yamanouchi Pharmaceutical Co., Ltd. Coated fine particles containing drug for intrabuccally fast disintegrating tablet
EP1677770A2 (en) * 2003-10-31 2006-07-12 Dexcel Ltd. Stable lansoprazole formulation
WO2005046634A2 (de) * 2003-11-14 2005-05-26 Siegfried Generics International Ag Magensaftresistente verabreichungsform
HU227317B1 (en) * 2003-11-25 2011-03-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Enteric coated tablet containing pantoprazole
US20050244490A1 (en) * 2003-12-09 2005-11-03 Michael Otto Dosing methods for beta-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine antiviral therapy
AU2005213472A1 (en) * 2004-02-10 2005-08-25 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent
AU2005226357B2 (en) * 2004-03-25 2010-07-01 Astellas Pharma Inc. Composition for solid pharmaceutical preparation of solifenacin or salt thereof
BRPI0509135A (pt) * 2004-03-26 2007-08-28 Eisai R&D Man Co Ltd composição farmacêutica de liberação controlada e método para produzir a mesma
PL1746980T3 (pl) * 2004-05-07 2012-03-30 Nycomed Gmbh Farmaceutyczna postać dawkowania zawierająca peletki i sposób jej wytwarzania
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20050281876A1 (en) * 2004-06-18 2005-12-22 Shun-Por Li Solid dosage form for acid-labile active ingredient
US20060024362A1 (en) * 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
DE102004042139B4 (de) * 2004-08-31 2009-06-10 Aristocon Verwaltungs- Gmbh Perorale Darreichungsformen zur Erzielung eines Retardierungseffektes nach der Arzneimitteleinnahme mit einer Mahlzeit
WO2006066932A1 (en) * 2004-12-24 2006-06-29 Lek Pharmaceuticals D.D. Stable pharmaceutical composition comprising an active substance in the form of solid solution
WO2006070735A1 (ja) * 2004-12-27 2006-07-06 Astellas Pharma Inc. ソリフェナシンまたはその塩の安定な粒子状医薬組成物
US20090208575A1 (en) * 2005-01-03 2009-08-20 Lupin Limited Pharmaceutical Composition Of Acid Labile Substances
US8673352B2 (en) 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
WO2007029124A2 (en) * 2005-05-13 2007-03-15 Combino Pharm, S.L. Formulations containing pantoprazole free acid and its salts
US7815939B2 (en) * 2005-07-20 2010-10-19 Astellas Pharma Inc. Coated fine particles containing drug for intrabuccally fast disintegrating dosage forms
EP1747776A1 (en) * 2005-07-29 2007-01-31 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising granular pantoprazole
EP1930030A1 (en) * 2005-09-29 2008-06-11 Eisai R&D Management Co., Ltd. Pulse preparation having improved disintegration properties in vivo
CN101309917B (zh) * 2005-10-06 2013-09-11 奥斯拜客斯制药有限公司 具有增强治疗性质的胃h+，k+-atp酶氘代抑制剂
EP1967211A4 (en) 2005-12-28 2009-12-30 Takeda Pharmaceutical PROCESS FOR PRODUCING SOLID PREPARATION DISINTEGRATING IN ORAL CAVITY
JP2009523784A (ja) * 2006-01-16 2009-06-25 ジュビラント・オルガノシス・リミテッド 酸不安定化合物の安定な医薬製剤およびその製造方法
JP2009538901A (ja) * 2006-06-01 2009-11-12 デクセル ファーマ テクノロジーズ エルティーディー． 複式ユニット製薬的製剤
GB2459393B (en) 2006-10-05 2010-09-08 Santarus Inc Novel capsule formulation for the proton pump inhibitor omeprazole
WO2008062320A2 (en) * 2006-10-06 2008-05-29 Eisai R&D Management Co., Ltd Extended release formulations of a proton pump inhibitor
WO2008057802A2 (en) 2006-10-27 2008-05-15 The Curators Of The University Of Missouri Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same
EP2478895A3 (en) 2006-12-22 2012-12-19 Ironwood Pharmaceuticals, Inc. Compositions for treating esophageal disorders
PL2224914T3 (pl) 2007-09-14 2015-11-30 Wockhardt Ltd Kompozycje diacereiny
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
DE102010052847A1 (de) * 2010-11-29 2012-05-31 Temmler Werke Gmbh Verfahren zur Herstellung einer PPI-haltigen pharmazeutischen Zubereitung
CN105338958A (zh) 2013-01-15 2016-02-17 铁木医药有限公司 胆汁酸螯合剂的胃内滞留缓释口服剂型
US20180015118A1 (en) 2015-02-03 2018-01-18 Ironwood Pharmaceuticals, Inc. Methods of treating upper gastrointestinal disorders in ppi refractory gerd
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CN108065443B (zh) * 2017-12-30 2020-02-28 厦门金达威维生素有限公司 斥水型双包被微胶囊及其制备方法
CN114569579B (zh) 2020-12-02 2023-10-31 丽珠医药集团股份有限公司 肠溶微丸、其制备方法和包含它的制剂
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2189699A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
JPH0768125B2 (ja) * 1988-05-18 1995-07-26 エーザイ株式会社 酸不安定化合物の内服用製剤

Also Published As

Publication number Publication date
PL169951B1 (pl) 1996-09-30
ZA924386B (en) 1993-02-24
FI935677A0 (fi) 1993-12-16
HRP920162A2 (en) 1996-08-31
IL102096A0 (en) 1993-01-14
JPH06508118A (ja) 1994-09-14
SI9200111A (en) 1992-12-31
GR3022154T3 (en) 1997-03-31
IL102096A (en) 1996-06-18
WO1992022284A1 (de) 1992-12-23
UA32525C2 (uk) 2001-02-15
US5997903A (en) 1999-12-07
AU1974692A (en) 1993-01-12
RU2089180C1 (ru) 1997-09-10
DE4219390A1 (de) 1992-12-24
ATE144416T1 (de) 1996-11-15
EP0589981A1 (de) 1994-04-06
IE77640B1 (en) 1997-12-31
YU57692A (sh) 1995-03-27
NO934648L (no) 1993-12-16
KR100254021B1 (ko) 2000-05-01
CZ276493A3 (en) 1994-07-13
RO117502B1 (ro) 2002-04-30
LV11982B (lv) 1998-09-20
SK278566B6 (en) 1997-10-08
ES2096080T3 (es) 1997-03-01
CN1037932C (zh) 1998-04-08
FI935677L (fi) 1993-12-16
BG61796B1 (bg) 1998-06-30
CN1067809A (zh) 1993-01-13
NO303714B1 (no) 1998-08-24
JP3338052B2 (ja) 2002-10-28
NZ243147A (en) 1995-12-21
CA2524168A1 (en) 1992-12-23
DK0589981T3 (da) 1997-03-17
BG98286A (bg) 1994-08-30
CA2109697A1 (en) 1992-12-23
TW224429B (enExample) 1994-06-01
IE921733A1 (en) 1992-11-18
YU48263B (sh) 1997-09-30
HK1005851A1 (en) 1999-01-29
ZW9392A1 (en) 1993-02-17
EP0519365A1 (de) 1992-12-23
FI101598B1 (fi) 1998-07-31
KR940701256A (ko) 1994-05-28
HRP920162B1 (en) 1998-08-31
AU683411B2 (en) 1997-11-13
DE59207438D1 (de) 1996-11-28
EP0589981B1 (de) 1996-10-23
SK128793A3 (en) 1994-06-08
NO934648D0 (no) 1993-12-16
CZ281697B6 (cs) 1996-12-11
MX9202961A (es) 1993-02-01
FI101598B (fi) 1998-07-31
LV11982A (lv) 1998-03-20

Similar Documents

Publication Publication Date Title
CA2109697C (en) Oral-administration forms of a medicament containing pantoprazole
HK1005851B (en) Oral-administration forms of a medicament containing pantoprazol
US20020128293A1 (en) Stable oral pharmaceutical composition containing omeprazole
EP1105105B1 (en) Oral administration form for pyridin-2-ylmethylsulfinyl-1h-benzimidazoles
WO2015145462A1 (en) Pharmaceutical compositions of dabigatran
AU2002366029B2 (en) Preparation compositions containing acid-unstable physiologically active compounds and process for producing the same
US8865212B2 (en) Stable pharmaceutical formulation of an acid labile compound and process for preparing the same
CA2540105A1 (en) Enteric soft gelatin capsule containing esomeprazole and method of preparation
WO2005034924A1 (en) Enteric coated pellets comprising esomeprazole, hard gelatin capsule containing them, and method of preparation
WO2004098573A1 (en) An improved and stable pharmaceutical composition containing substituted benzimidazoles and a process for its preparation
EP1594479A1 (en) Stable oral benzimidazole compositions and processes for their preparation
JP2001270827A (ja) ベンズイミダゾール系化合物含有錠剤
HU227317B1 (en) Enteric coated tablet containing pantoprazole
KR100570446B1 (ko) 산 불안정성 약리활성물질 함유 장용성 경구용 제제 및 이의 제조방법
WO2004075881A1 (en) Stable pharmaceutical composition of rabeprazole and processes for their preparation
KR20070020977A (ko) 판토프라졸 함유 경구용 약제 제형
HK1068271A (en) Preparation compositions containing acid-unstable physiologically active compounds and process for producing the same
HU219247B (en) Oral administration form of a medicament containing pantoprazol

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry